Mi-ot, Laiza .
HRN: 22-66-22 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/18/2023
CO-AMOXICLAV 625MG (TAB)
01/18/2023
01/25/2023
PO
625 Mg Tab
BID
S/P NSVD With RMLE And Repair, UTI
Waiting Final Action
Indication: Empiric Type of Infection: Urinary TractReproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes